News

Genetic MR links gut microbiome shifts to eczema, dermatitis, rosacea and more, spotlighting cytokines like IL‑10, IL‑18 and IL‑6 as therapeutic targets.

Bradley Burnam, founder and CEO of Turn Therapeutics, discussed GX-03's encouraging interim safety profile, regulatory strategy, and next steps in clinical development.

Black Girl Sunscreen CEO and founder reveals why daily SPF matters for deeper skin tones, tackling white cast, education gaps, and inclusive sun care testing.

TRAPEDS-1 met its primary pharmacokinetic objective in children aged 6 to 11 years with moderate to severe atopic dermatitis, with no new safety signals over up to 172 weeks of tralokinumab treatment.

A new real-world study found CSU was linked to stress-related disorders, but not a broad increase in new-onset psychiatric disease.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Recapping 5 practice-changing FDA decisions from the first half of 2026, including icotrokinra, expanded pediatric indications, and more!

Christopher Bunick, MD, PhD, shared practical guidance on sun protection, swimming, and preserving the skin barrier in patients with atopic dermatitis.

In this episode, Black Girl Sunscreen CEO Shontay Lundy reveals why skin of color needs photoprotection, better formulas, and stronger clinician-industry collaboration.

Forte Biosciences' FB102 shows significant facial repigmentation in a phase 1b vitiligo trial, with gains continuing 12 weeks post-treatment and mild adverse effects.

Learn the 10 weekly dashboard metrics Kathleen Moe, MD, tracks to spot issues early, boost access, cash flow, and patient experience in her practice.

Lynk Pharmaceuticals has dosed the first patient in a phase 2 trial evaluating investigational topical pan-JAK inhibitor LNK01004 for vitiligo.

Bradley Burnam, founder and CEO of Turn Therapeutics, explains the statistical rationale behind GX-03's phase 2 end point strategy and patient stratification.

Philip J. Mease, MD, explains the rationale for early biologic treatment in psoriatic arthritis following guselkumab's FDA label expansion to address structural joint damage.

A JAMA Dermatology study suggests higher cumulative isotretinoin doses, not higher daily doses, may help reduce acne relapse.

Roman Bronfenbrener, MD, discussed how dermatologists are using AI to streamline documentation, summarize patient records, support clinical decision-making, and improve practice operations.

FDA clears SkinStylus microneedling for under-eye wrinkles in all skin types, expanding uses for acne and abdominal scars amid booming aesthetics demand.

The FDA accepted Arcutis' supplemental NDA seeking to expand roflumilast cream 0.05% to infants aged 3 months to younger than 2 years with mild to moderate AD.

This review of the latest dermatological studies includes insights on granulomatous dermatoses during dupilumab therapy, SAAD-41 validation in alopecia, updated vitiligo trends, and more.

Bradley Burnam, founder and CEO of Turn Therapeutics, discussed interim phase 2 trial findings showing GX-03 efficacy across a broader range of EASI severity scores in atopic dermatitis.

A 30-day trial finds multi-step, barrier-friendly skin care routine cuts acne lesions, oil and redness while boosting hydration in acne-prone skin.

A recent JAAD study identified a dual Th17/Type 2 immune signature in psoriasis that may help explain why biologic responses vary among patients.

Teva Pharmaceuticals will advance TEV-'408 into phase 2b after encouraging phase 1b vitiligo data showed repigmentation, favorable safety, and quarterly dosing potential.

New case-control data link smoking to higher nail psoriasis severity, urging screening and cessation to ease nail symptoms and boost quality of life.

Turn Therapeutics finalized its stage 2 trial design after interim data showed clinically meaningful GX-03 efficacy in patients with baseline EASI scores as low as 1.1.

Philip Mease, MD, reviews the APEX trial data supporting guselkumab's expanded FDA label for inhibition of structural joint damage in psoriatic arthritis.

At a recent Dermatology Times Evolving Paradigms event, Nikhil Khushalani, MD, led dermatologists, Mohs surgeons, and oncologists in comparing systemic immunotherapy selection, referral practices, and adverse event management in advanced cutaneous squamous cell carcinoma.

Can-Fite completed interim enrollment for its pivotal phase 3 trial of first-in-class oral A3AR agonist piclidenoson, a potential new mechanism for plaque psoriasis.

LEADderm, led by Jennifer Soung, MD, helps dermatologists build leadership, AI readiness, and purpose-driven careers—leaving attendees energized, connected, and patient-focused.

Linda Stein Gold, MD, discusses zasocitinib's safety and efficacy as an oral treatment for plaque psoriasis.